[
  {
    "ts": null,
    "headline": "Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical",
    "summary": "Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and strategic moves in new reports.",
    "url": "https://finnhub.io/api/news?id=fa9c6321ca4540cde11cc1b401cec95ab439bee99fcd494c2675800e0cd747b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748549700,
      "headline": "Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical",
      "id": 134863944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and strategic moves in new reports.",
      "url": "https://finnhub.io/api/news?id=fa9c6321ca4540cde11cc1b401cec95ab439bee99fcd494c2675800e0cd747b0"
    }
  },
  {
    "ts": null,
    "headline": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
    "summary": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
    "url": "https://finnhub.io/api/news?id=f272a3cef6c1df46d6329ad9d7ad6e60f6ca021b1a417de3d2151a63ce6949b0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748527740,
      "headline": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
      "id": 134895320,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
      "url": "https://finnhub.io/api/news?id=f272a3cef6c1df46d6329ad9d7ad6e60f6ca021b1a417de3d2151a63ce6949b0"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?",
    "summary": "ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.",
    "url": "https://finnhub.io/api/news?id=9959144bf0926e5d721d64c7a15e12f33040494da070be2e78c6d69f24936658",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748525460,
      "headline": "AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?",
      "id": 134848328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.",
      "url": "https://finnhub.io/api/news?id=9959144bf0926e5d721d64c7a15e12f33040494da070be2e78c6d69f24936658"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Fairly Valued, But Lacking A Spark",
    "summary": "AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside. Read why ABBV stock is a hold.",
    "url": "https://finnhub.io/api/news?id=1619cd3d17dc362f0d44a30e343b9044f5ee9111f9da737355204ef4253f467b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748508061,
      "headline": "AbbVie: Fairly Valued, But Lacking A Spark",
      "id": 134804923,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2169470466/image_2169470466.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside. Read why ABBV stock is a hold.",
      "url": "https://finnhub.io/api/news?id=1619cd3d17dc362f0d44a30e343b9044f5ee9111f9da737355204ef4253f467b"
    }
  },
  {
    "ts": null,
    "headline": "When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does",
    "summary": "Money market funds are booming with $7.2 trillion in assets. Read why LMT, ABBV, VICI stocks could significantly benefit from this money market rotation trend.",
    "url": "https://finnhub.io/api/news?id=5f306c40043930a0e364024044ff64e7d9466d2fd42d0237d0904448f4c3a697",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748503800,
      "headline": "When $7 Trillion Wakes Up: Buy These 3 Dividend Stocks Before Everyone Else Does",
      "id": 134801809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158443315/image_2158443315.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Money market funds are booming with $7.2 trillion in assets. Read why LMT, ABBV, VICI stocks could significantly benefit from this money market rotation trend.",
      "url": "https://finnhub.io/api/news?id=5f306c40043930a0e364024044ff64e7d9466d2fd42d0237d0904448f4c3a697"
    }
  },
  {
    "ts": null,
    "headline": "TCW Relative Value Large Cap Fund Q1 2025 Commentary",
    "summary": "TCW Relative Value Large Cap Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=5c468935eeed3302bc71bba57bfa5156ce86a0236039f8631a3606ccf4ffbbaa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748499360,
      "headline": "TCW Relative Value Large Cap Fund Q1 2025 Commentary",
      "id": 134801243,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5c468935eeed3302bc71bba57bfa5156ce86a0236039f8631a3606ccf4ffbbaa"
    }
  },
  {
    "ts": null,
    "headline": "Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm",
    "summary": "NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=b82495d9052e42a465b75c3351ac6a4afb9b3f7b3a9f6fd5c5fdaf83882b5d03",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748497569,
      "headline": "Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm",
      "id": 134800992,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=b82495d9052e42a465b75c3351ac6a4afb9b3f7b3a9f6fd5c5fdaf83882b5d03"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat",
    "summary": "AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response […]",
    "url": "https://finnhub.io/api/news?id=ab1d1d4955d4a1097b9eef3d1b018a078d03e879eb91e7839a7e0ede96940bea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748492350,
      "headline": "AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat",
      "id": 134811863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response […]",
      "url": "https://finnhub.io/api/news?id=ab1d1d4955d4a1097b9eef3d1b018a078d03e879eb91e7839a7e0ede96940bea"
    }
  }
]